axelopran

DRUG3 trials

Sponsors

HealthPartners Institute, John Kirkwood, Glycyx Therapeutics

Conditions

Breast CancerHead and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)Lung CancerPancreas CancerProstate CancerUnresectable Cutaneous Melanoma

Phase 1

Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma

Not yet recruitingNCT07631325

John KirkwoodUnresectable Cutaneous Melanoma

Start: 2026-10-31End: 2030-07-31Target: 28Updated: 2026-07-13

A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer

Not yet recruitingNCT07662720

Glycyx TherapeuticsHead and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

Start: 2026-07-15End: 2028-08-31Target: 18Updated: 2026-07-15

Phase 2

Axelopran for Advanced Cancer in Patients Receiving Opioids

RecruitingNCT07354919

HealthPartners InstituteBreast Cancer, Lung Cancer, Pancreas Cancer +1

Start: 2026-04-27End: 2028-11-01Target: 34Updated: 2026-05-05